SCHEMBL4864178

SCHEMBL4864178

COc1cc(C2=NNC(=O)C2=NNc2ccc(C)c(-c3cccnc3)c2)cc(OC)c1OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 3/20 0.43
FGFR1 P11362 3/20 0.43
KDR P35968 3/20 0.43
PDGFRB P09619 1/20 0.41
BRAF P15056 1/20 0.40
PRKD3 O94806 1/20 0.40
PRKCG P05129 1/20 0.40
PRKCB P05771 1/20 0.40
LCK P06239 1/20 0.40
PRKCA P17252 1/20 0.40
PRKCH P24723 1/20 0.40
PRKCI P41743 1/20 0.40
ZAP70 P43403 1/20 0.40
PRKCE Q02156 1/20 0.40
PRKCQ Q04759 1/20 0.40
PRKCZ Q05513 1/20 0.40
PRKCD Q05655 1/20 0.40
PRKD1 Q15139 1/20 0.40
POLB P06746 1/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4864163 1.00 EGFR (0.43) EGFRFGFR1KDRPDGFRBBRAF
SCHEMBL4865287 0.90 BRD4 (0.39) KDRMAPK1HTTBRD4TUBB4A
SCHEMBL4865283 0.90 BRD4 (0.39) KDRMAPK1HTTBRD4TUBB4A
SCHEMBL4863304 0.89 BRD4 (0.36) EGFRFGFR1KDRBRAFMAPK1
SCHEMBL4863327 0.89 BRD4 (0.36) EGFRFGFR1KDRBRAFMAPK1
SCHEMBL4867109 0.86 CYP11B1 (0.42) CYP1A2HTR2AHTR2CHTR2BCTSD
SCHEMBL4867111 0.86 CYP11B1 (0.42) CYP1A2HTR2AHTR2CHTR2BCTSD
SCHEMBL4855994 0.86 FYN (0.42) KDRBRD4TUBB4ATUBBTUBA3C
SCHEMBL4855988 0.86 FYN (0.42) KDRBRD4TUBB4ATUBBTUBA3C
SCHEMBL4859138 0.86 PDGFRB (0.39) KDRPDGFRBMAPK1HTTBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7452873-B2 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-18 US disclosed
US-20050222237-A1 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2005-10-06 US disclosed
US-6916798-B2 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-07-12 US disclosed
US-20040024040-A1 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2004-02-05 US disclosed
WO-2003011287-A1 PYRAZOLON DERIVATIVES AS INHIBITORS OF GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2003-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024040-A1 Inhibitors of GSK-3 and uses thereof GSK3B, AURKC, GSK3A EGFR 895/4885FGFR1 817/4885KDR 3315/4885
US-20050222237-A1 Inhibitors of GSK-3 and uses thereof GSK3B, AURKC, GSK3A EGFR 895/4885FGFR1 817/4885KDR 3315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.